<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01376869</url>
  </required_header>
  <id_info>
    <org_study_id>21AO1</org_study_id>
    <nct_id>NCT01376869</nct_id>
  </id_info>
  <brief_title>Investigation of the Acute Cognitive, Mood and Autonomic Effects of Hops in Healthy Participants</brief_title>
  <official_title>Investigation of the Acute Cognitive, Mood and Autonomic Effects of Hops in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northumbria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The New Zealand Institute for Plant and Food Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northumbria University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hops have been used for many years for their supposed sedative and anxiety reducing&#xD;
      properties and can be found in many natural remedies for stress, anxiety and sleeping that&#xD;
      are already available to buy.&#xD;
&#xD;
      However, human trials investigating the effects of hops have so far been limited to the&#xD;
      effects of the combination of hops and valerian in relation to sleep. Such studies have&#xD;
      identified that a valerian-hops mixture can result in improved sleep but Valerian alone has&#xD;
      no effect.&#xD;
&#xD;
      The current study aims to investigate the effect of hops alone in healthy human participants&#xD;
      aged 18-35 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mood</measure>
    <time_frame>across 3 hours</time_frame>
    <description>Mood as assessed by STAI, Bond-Lader mood scales, POMS, DEQ and stress/euphoria/sedation visual analogue scales (VAS).&#xD;
The shift in mood (STAI, Bond-Lader, POMS, DEQ, Stress/Euphoria/Sedation VAS) inculcated by completion of cognitive tasks.&#xD;
Heart rate and blood pressure.&#xD;
The modulation of blood pressure and heart rate inculcated by completion of cognitive tasks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satiety</measure>
    <time_frame>across 3 hours</time_frame>
    <description>Satiety as assessed by VAS (hungry/full/desire to eat/food intake).&#xD;
The modulation of satiety (VAS) inculcated by completion of the cognitive tasks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bioavailability of Hops</measure>
    <time_frame>across 3 hours</time_frame>
    <description>â€¢ Plasma hops levels are to be examined to assess bioavailability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognition</measure>
    <time_frame>across 3 hours</time_frame>
    <description>Performance on working memory tasks (2-back and logical reasoning).&#xD;
Performance on serial subtraction element of a dual task.&#xD;
Performance on word and picture recognition tasks.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Mood Modulation</condition>
  <condition>Modulation of Cognition</condition>
  <arm_group>
    <arm_group_label>102mg extract 1 hops</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Equivalent to 0.5g dry weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>410mg extract 1 hops</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Equivalent to 2g dry weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>79mg extract 2 hops</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Equivalent to 0.5g dry weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>316mg extract 2 hops</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Equivalent to 2g dry weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Hops Extract</intervention_name>
    <description>All 150 participants will complete 1 study visit; receiving either of the 4 hops doses or placebo (silica). Computer generated random numbers will be used to allocate treatments to participant identification numbers. Treatment will be administered in capsule form and in a double blind manner.</description>
    <arm_group_label>102mg extract 1 hops</arm_group_label>
    <arm_group_label>316mg extract 2 hops</arm_group_label>
    <arm_group_label>410mg extract 1 hops</arm_group_label>
    <arm_group_label>79mg extract 2 hops</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo (silica)</intervention_name>
    <description>All 150 participants will complete 1 study visit; receiving either of the 4 hops doses or placebo (silica). Computer generated random numbers were used to allocate treatments to participant identification numbers. Treatment will be administered in capsule form and in a double blind manner.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male/female,&#xD;
&#xD;
          -  Healthy&#xD;
&#xD;
          -  Age 18-35 years old&#xD;
&#xD;
          -  Non smoker&#xD;
&#xD;
          -  Proficient in English&#xD;
&#xD;
          -  Not taking any herbal or prescription medications&#xD;
&#xD;
          -  Not pregnant seeking to become pregnant or breastfeeding&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy or hypersensitivity to any of the ingredients contained in the investigational&#xD;
             product or any other foodstuff.&#xD;
&#xD;
          -  Vegetarian (as the capsules contain gelatine).&#xD;
&#xD;
          -  Have a history of neurological, vascular or psychiatric illness (including depressive&#xD;
             illness and anxiety).&#xD;
&#xD;
          -  Have a current/ history of drug or alcohol abuse.&#xD;
&#xD;
          -  Currently take medication (excluding the contraceptive pill).&#xD;
&#xD;
          -  High Blood Pressure (&gt;140/90)&#xD;
&#xD;
          -  BMI outside of the range 18- 34.9&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Crystal Haskell</last_name>
    <role>Study Director</role>
    <affiliation>Northumbria University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northumbria University</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 8ST</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>June 16, 2011</study_first_submitted>
  <study_first_submitted_qc>June 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2011</study_first_posted>
  <last_update_submitted>June 22, 2012</last_update_submitted>
  <last_update_submitted_qc>June 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northumbria University</investigator_affiliation>
    <investigator_full_name>Crystal Haskell</investigator_full_name>
    <investigator_title>Research Fellow</investigator_title>
  </responsible_party>
  <keyword>Hops</keyword>
  <keyword>Mood</keyword>
  <keyword>Cognitive Function</keyword>
  <keyword>Bioavailability</keyword>
  <keyword>Satiety</keyword>
  <keyword>Blood Pressure</keyword>
  <keyword>Heart rate</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

